Theravance Biopharma (TBPH) News Today $9.79 +0.29 (+3.05%) As of 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Zacks Research Issues Positive Outlook for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research boosted their Q1 2027 earnings estimates for Theravance Biopharma in a report issued on Wednesday, April 23rd. Zacks Research analyst R. Department now expects that the biopharmaceutical company will earn ($0.40)April 29 at 2:55 AM | marketbeat.comTheravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA CongressApril 28 at 6:00 AM | prnewswire.comQ1 EPS Estimate for Theravance Biopharma Lifted by AnalystApril 28 at 2:57 AM | americanbankingnews.comRep. George Whitesides Sells Theravance Biopharma, Inc. (NASDAQ:TBPH) StockRepresentative George Whitesides (D-California) recently sold shares of Theravance Biopharma, Inc. (NASDAQ:TBPH). In a filing disclosed on April 23rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Theravance Biopharma stock on March 24th. The trade occurred in the RApril 28 at 2:02 AM | marketbeat.comJPMorgan Chase & Co. Reduces Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)JPMorgan Chase & Co. trimmed its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 17.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 219,568 shares of the biopharmaceutical company's stockApril 27 at 3:08 AM | marketbeat.comTheravance Biopharma to Report First Quarter 2025 Financial Results on May 8, 2025April 24, 2025 | prnewswire.comInsider Selling: Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Sells 4,000 Shares of StockApril 24, 2025 | insidertrades.comVanguard Group Inc. Lowers Stake in Theravance Biopharma, Inc. (NASDAQ:TBPH)Vanguard Group Inc. lessened its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 2.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,010,544 shares of the biopharmaceutical company's stock after selling 41,145 sApril 19, 2025 | marketbeat.comTrexquant Investment LP Buys 50,826 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Trexquant Investment LP increased its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 50.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 151,083 shares of the biopharmaceutical company's stApril 12, 2025 | marketbeat.comTheravance Biopharma Presents Two New Ampreloxetine Analyses in Oral Session at the American Academy of Neurology 2025 Annual MeetingApril 7, 2025 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceMarch 31, 2025 | prnewswire.comTheravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of NeurologyMarch 27, 2025 | prnewswire.comQ1 EPS Forecast for Theravance Biopharma Reduced by AnalystTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Investment analysts at Zacks Research dropped their Q1 2025 EPS estimates for shares of Theravance Biopharma in a report released on Wednesday, March 19th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical companMarch 24, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Consensus Recommendation of "Hold" from AnalystsShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus rating of "Hold" by the five analysts that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendatioMarch 23, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Crosses Above 50-Day Moving Average - What's Next?Theravance Biopharma (NASDAQ:TBPH) Share Price Crosses Above 50-Day Moving Average - What's Next?March 18, 2025 | marketbeat.comTheravance Biopharma: Clinical Progress Is Not Enough To Make It AttractiveMarch 10, 2025 | seekingalpha.comWhat is Zacks Research's Forecast for TBPH Q1 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Analysts at Zacks Research decreased their Q1 2026 EPS estimates for Theravance Biopharma in a research note issued to investors on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the biopharmaceutical coMarch 3, 2025 | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comTheravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings ResultsTheravance Biopharma (NASDAQ:TBPH - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.26). Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%.February 27, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for TBPH FY2024 Earnings?Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Stock analysts at HC Wainwright issued their FY2024 earnings per share estimates for Theravance Biopharma in a research report issued on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceutical company wiFebruary 27, 2025 | marketbeat.comTheravance Biopharma reports Q4 EPS (31c), consensus (8c)February 27, 2025 | markets.businessinsider.comTheravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | prnewswire.comResearch Analysts Set Expectations for TBPH FY2028 EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities researchers at HC Wainwright issued their FY2028 earnings estimates for shares of Theravance Biopharma in a research note issued to investors on Tuesday, February 25th. HC Wainwright analyst D. Tsao anticipates that the biopharmaceFebruary 26, 2025 | marketbeat.comEarnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 ResultFebruary 25, 2025 | finance.yahoo.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Average Recommendation of "Hold" by BrokeragesShares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given an average recommendation of "Hold" by the five analysts that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and two have issued a buy ratingFebruary 25, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Earns "Buy" Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a research note on Tuesday.February 25, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Shares Cross Above 50 Day Moving Average - Here's WhyTheravance Biopharma (NASDAQ:TBPH) Stock Price Passes Above Fifty Day Moving Average - Here's WhyFebruary 25, 2025 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 20, 2025 | prnewswire.comTheravance Biopharma (TBPH) Projected to Post Quarterly Earnings on MondayTheravance Biopharma (NASDAQ:TBPH) will be releasing earnings after the market closes on Monday, February 24. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665706)February 17, 2025 | marketbeat.comTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025February 12, 2025 | prnewswire.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceFebruary 5, 2025 | prnewswire.comTheravance Biopharma (NASDAQ:TBPH) Reaches New 52-Week High - Here's WhyTheravance Biopharma (NASDAQ:TBPH) Hits New 1-Year High - Here's WhyJanuary 25, 2025 | marketbeat.comTheravance Biopharma stock hits 52-week high at $10.47January 24, 2025 | msn.comTheravance Biopharma (NASDAQ:TBPH) Shares Up 8.8% - Still a Buy?Theravance Biopharma (NASDAQ:TBPH) Trading Up 8.8% - Time to Buy?January 24, 2025 | marketbeat.comTheravance biopharma SVP Rhonda Farnum sells $36,000 in sharesJanuary 24, 2025 | msn.comRhonda Farnum Sells 4,000 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) StockJanuary 24, 2025 | insidertrades.comTheravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum Sells 4,000 SharesTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now owns 309,565 shares of the company's stock, valued at $2,786,085. The trade was a 1.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.January 23, 2025 | marketbeat.comBarclays PLC Increases Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)Barclays PLC grew its stake in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 279.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 65,580 shares of the biopharmaceutical company's stock aJanuary 18, 2025 | marketbeat.comZacks Research Issues Positive Forecast for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Research analysts at Zacks Research lifted their Q2 2026 earnings estimates for Theravance Biopharma in a report released on Monday, January 13th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will poJanuary 16, 2025 | marketbeat.comAnalysts Are Optimistic We'll See A Profit From Theravance Biopharma, Inc. (NASDAQ:TBPH)January 7, 2025 | uk.finance.yahoo.comState Street Corp Decreases Stock Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)State Street Corp lowered its stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 6.0% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 1,191,621 shares of the biopharmaceutical company's stock after selling 75,754 shares during the quartDecember 27, 2024 | marketbeat.comWellington Management Group LLP Sells 159,258 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)Wellington Management Group LLP lessened its position in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 45.4% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 191,329 shares of the biopharmaceutical comDecember 19, 2024 | marketbeat.comTheravance Biopharma to Conduct Investor Meetings During the J.P. Morgan 43rd Annual Healthcare ConferenceDecember 17, 2024 | prnewswire.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from AnalystsTheravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has been given an average recommendation of "Hold" by the five brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and two have issued aDecember 9, 2024 | marketbeat.comBNP Paribas Financial Markets Acquires 143,781 Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH)BNP Paribas Financial Markets raised its holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 88.9% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 305,480 shares of the biopharmaceutical company's stockDecember 7, 2024 | marketbeat.comZacks Research Issues Pessimistic Outlook for TBPH EarningsTheravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities researchers at Zacks Research dropped their FY2024 earnings per share (EPS) estimates for shares of Theravance Biopharma in a research report issued to clients and investors on Tuesday, December 3rd. Zacks Research analyst R. DeparDecember 6, 2024 | marketbeat.comAlgert Global LLC Invests $851,000 in Theravance Biopharma, Inc. (NASDAQ:TBPH)Algert Global LLC bought a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) during the third quarter, according to its most recent filing with the SEC. The firm bought 105,609 shares of the biopharmaceutical company's stock, valued at approximately $851,000. Algert Global LLC ownNovember 30, 2024 | marketbeat.comTheravance Biopharma to Participate in an Upcoming Investor ConferenceNovember 20, 2024 | prnewswire.comTheravance Biopharma’s Third Quarter 2024 Financial InsightsNovember 14, 2024 | markets.businessinsider.com Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address TBPH Media Mentions By Week TBPH Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TBPH News Sentiment▼0.880.85▲Average Medical News Sentiment TBPH News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TBPH Articles This Week▼122▲TBPH Articles Average Week Get Theravance Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BLTE News JANX News SDGR News ARWR News CNTA News SUPN News GLPG News IDYA News ARQT News TVTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TBPH) was last updated on 4/30/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredYou’re About to Lose Everything – Act Now or Regret It ForeverWhat If America's Gold Reserves Are a Lie? For decades, the U.S. government has claimed to have thousands o...Hamilton Gold Group | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theravance Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theravance Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TBPH Stock Free TBPH Stock Alerts